Central imidazoline- and alpha 2-receptors involved in the cardiovascular actions of centrally acting antihypertensive agents.
There has been a continuing and yet unresolved debate concerning the existence and contribution of imidazoline receptors to the antihypertensive actions of clonidine-like agents. Studies from our laboratory have examined the importance of imidazoline receptors and alpha 2-adrenoceptors in the mechanism of action of centrally acting antihypertensive drugs. We used conscious rabbits and imidazoline and specific alpha 2-adrenoceptor antagonists to show that second-generation agents rilmenidine and moxonidine act preferentially through imidazoline receptors but that alpha 2-adrenoceptors are important for the hypotension produced by clonidine and alpha-methyldopa. Using microinjections of the imidazoline antagonists into the rostral ventrolateral medulla (RVLM) of anesthetized rabbits we confirmed the generally held view that this is the major site of sympathoinhibitory actions of centrally acting antihypertensive agents. However, we also found that alpha 2-adrenoceptors are present in this nucleus and appear to be activated as a consequence of imidazoline receptor activation. In recent studies using a noradrenergic neurotoxin microinjected into the RVLM we found that this treatment selectively blocked the actions of moxonidine but did not affect the level of imidazole proteins, suggesting that I1-imidazoline receptors may be located presynaptic to the noradrenergic terminal. By contrast, clonidine acts directly on the alpha 2-adrenoceptors perhaps located on cell bodies in the nucleus. In conclusion, our studies suggest that imidazoline receptors and alpha 2-adrenoceptors within the RVLM are important for the antihypertensive actions of clonidine-like drugs.
Neuropharmacology Laboratory, Baker Medical Research Institute, Prahran, Victoria, Australia. Geoff.Head@baker.edu.au
G A
GA
Head
D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D003000:Clonidine / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D054755:Imidazoline Receptors; D008526:Medulla Oblongata / Q000187:drug effects / Q000502:physiology*; D008845:Microinjections; D008959:Models, Neurological; D009638:Norepinephrine / Q000502:physiology; D010080:Oxazoles / Q000494:pharmacology; D011817:Rabbits; D018341:Receptors, Adrenergic, alpha-2 / Q000187:drug effects / Q000502:physiology*; D011955:Receptors, Drug / Q000037:antagonists & inhibitors / Q000502:physiology*; D000077769:Rilmenidine; D012701:Serotonin / Q000502:physiology; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology
D000316:Adrenergic alpha-Agonists; D000959:Antihypertensive Agents; D007093:Imidazoles; D054755:Imidazoline Receptors; D010080:Oxazoles; D018341:Receptors, Adrenergic, alpha-2; D011955:Receptors, Drug; D012701:Serotonin; C043482:moxonidine; D003000:Clonidine; D000077769:Rilmenidine; D009638:Norepinephrine